• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

SLAM BioTherapeutics, Inc.

Tuesday, June 04, 2024
Oncology
SLAM Bio is a preclinical stage biotech company developing a platform of antibodies and antibody drug conjugates (ADCs) against signaling lymphocytic activation molecule (SLAM) protein family. SLAM’s lead program is a first-in-class humanized antibody and ADC targeting CD84 (SLAMF5), a cell surface adhesion molecule that is expressed on immune cells and acts as a master regulator of the immune response. In oncology applications, we have preclinical proof of concept in AML, breast cancer, myeloma and CLL. We are developing an antibody drug conjugate (ADC) that can be applied on select antibodies in our portfolio.
Company Website: https://slambio.com/

Company HQ City

Phoenix

Company HQ State

AZ

Company HQ Country

United States

CEO/Top Company Official

Steven J. Potts, PhD
Speakers
Steven Potts
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS